RhoGAM® Rho(D) Immune Globulin (Human)

RhoGAM® Rho(D) Immune Globulin (Human) |

FETALSCREEN™ II FMH Test | RhoGAM® Rho(D) Immune Globulin (Human)

		Before the introduction of RhoGAM® Brand in 1968, roughly 10,000 babies died each year in the U.S. alone from Hemolytic Disease of the Newborn. Today, this condition has been virtually eliminated, saving hundreds of thousands of newborns from crippling birth defects and death. Millions of doses of RhoGAM® Brand have been administered to Rh-negative mothers worldwide, and Ortho Clinical Diagnostics has provided nearly 40 years of uninterrupted supply to protect even the tiniest patients. For more detailed information regarding the safe and effective use of RhoGAM® Brand please see the full prescribing information
		Important Safety Information RhoGAM^® and MICRhoGAM^® Ultra-Filtered PLUS Rho(D) Immune Globulin (Human) are made from human plasma. Since all plasma-derived products are made from human blood, they may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically the Creutzfeldt-Jakob disease (CJD) agent. RhoGAM^® and MICRhoGAM^® are intended for maternal administration. Do not inject the newborn infant. Local adverse reactions may include redness, swelling, and mild pain at the site of injection and a small number of patients have noted a slight elevation in temperature. Patients should be observed for at least 20 minutes after administration. Hypersensitivity reactions include hives, generalized urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis. RhoGAM^® and MICRhoGAM^® contain a small quantity of IgA and physicians must weigh the benefit against the potential risks of hypersensitivity reactions. Patients who receive RhoGAM^® and MICRhoGAM^® for Rh-incompatible transfusion should be monitored by clinical and laboratory means due to the risk of a hemolytic reaction. Request Product Information Complete Prescribing Information for RhoGAM® Ultra-Filtered PLUS For more information, click here to go to RhoGAM.com